We are live on ! Find out more
AI

Alphabet Inc Portfolio holdings

AUM $4.02B
1-Year Est. Return 215.74%
This Fund
S&P 500
This Quarter Est. Return
+11.05%
1 Year Est. Return
+215.74%
3 Year Est. Return
+350.01%
5 Year Est. Return
+242.03%
10 Year Est. Return
+998.87%
AUM
$4.91B
AUM Growth
+$2.43B
Cap. Flow
+$2.52B
Cap. Flow %
51.35%
Top 10 Hldgs %
89.16%
Holding
40
New
8
Increased
1
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$2.13B
2
VERV
Verve Therapeutics
VERV
+$456M
3
LYEL icon
Lyell Immunopharma
LYEL
+$96.2M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$29.8M
5
BRNS
Barinthus Biotherapeutics
BRNS
+$25.2M

Top Sells

Rank Stock Value
1
UPST icon
Upstart Holdings
UPST
+$107M
2
DM
Desktop Metal, Inc.
DM
+$42.7M
3
OPEN icon
Opendoor
OPEN
+$26.5M
4
ABNB icon
Airbnb
ABNB
+$26M
5
LMND icon
Lemonade
LMND
+$16.5M

Sector Composition

Rank Sector Weight
1 Technology 48.99%
2 Healthcare 46.65%
3 Industrials 2.59%
4 Consumer Discretionary 1.64%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$6.61B
$1.97B 40.17%
+29,025,785
New +$2.13B
VERV
2
DELISTED
Verve Therapeutics
VERV
$661M 13.47%
+10,974,011
New +$456M
OSCR icon
3
Oscar Health
OSCR
$9.41B
$517M 10.53%
24,042,864
– –
LYFT icon
4
Lyft
LYFT
$6.02B
$371M 7.56%
6,138,154
-282,831
-4% -$16.3M
DXCM icon
5
DexCom
DXCM
$31.5B
$344M 7.01%
3,222,724
– –
DM
6
DELISTED
Desktop Metal, Inc.
DM
$127M 2.59%
1,104,873
-325,371
-23% -$42.7M
RCUS icon
7
Arcus Biosciences
RCUS
$3.55B
$127M 2.58%
4,613,818
-109,530
-2% -$3.13M
LYEL icon
8
Lyell Immunopharma
LYEL
$317M
$95.3M 1.94%
+293,256
New +$96.2M
BEAM icon
9
Beam Therapeutics
BEAM
$2.63B
$81.8M 1.67%
635,586
-5,206
-0.8% -$415K
ABNB icon
10
Airbnb
ABNB
$89.9B
$80.5M 1.64%
525,626
-165,986
-24% -$26M
RLAY icon
11
Relay Therapeutics
RLAY
$4.1B
$66.8M 1.36%
1,826,876
+258,390
+16% +$8.52M
WORK
12
DELISTED
Slack Technologies, Inc.
WORK
$57.6M 1.17%
1,299,771
– –
SANA icon
13
Sana Biotechnology
SANA
$871M
$55.3M 1.13%
2,812,500
– –
CLOV icon
14
Clover Health Investments
CLOV
$2.2B
$54.8M 1.12%
4,113,742
– –
KRON
15
DELISTED
Kronos Bio
KRON
$34.4M 0.7%
1,438,232
– –
GLUE icon
16
Monte Rosa Therapeutics
GLUE
$1.4B
$33.2M 0.68%
+1,464,015
New +$29.8M
DNTH icon
17
Dianthus Therapeutics
DNTH
$5.84B
$32.7M 0.67%
208,696
– –
BRNS
18
Barinthus Biotherapeutics
BRNS
$22.8M
$28.6M 0.58%
+1,704,444
New +$25.2M
RAPT
19
DELISTED
RAPT Therapeutics
RAPT
$25.1M 0.51%
98,602
-5,305
-5% -$991K
OMIC
20
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$17.8M 0.36%
+21,554
New +$16.7M
IDYA icon
21
IDEAYA Biosciences
IDYA
$3.42B
$15.8M 0.32%
753,187
– –
EVLO
22
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$14.6M 0.3%
53,025
– –
DBTX
23
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$14.1M 0.29%
1,636,258
– –
TSHA icon
24
Taysha Gene Therapies
TSHA
$1.68B
$13.6M 0.28%
640,882
– –
VERA icon
25
Vera Therapeutics
VERA
$2.3B
$12.5M 0.26%
+944,791
New +$14.7M
1
2

Similar funds

JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
MAM
Martingale Asset Management Boston, Massachusetts $3.99B AUM 22.65% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
ICP
Ilex Capital Partners London, United Kingdom $4.06B AUM 6.11% 1-Year Est. Return
CA
CSM Advisors Warrendale, Pennsylvania $4.07B AUM 29.62% 1-Year Est. Return
MGP
Metis Global Partners San Diego, California $4.07B AUM 30.82% 1-Year Est. Return

Alphabet Inc's Q2 2021 Portfolio in Review

As of Q2 2021, Alphabet Inc held 40 positions worth $4.91B, up 98% from $2.48B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Alphabet Inc deployed $2.52B of net new capital in Q2 2021, opening 8 new positions and adding to 1 existing holding. Its largest new stake was UiPath: 29,025,785 shares worth $1.97B.

By sector, the portfolio is most concentrated in Technology at 49% of assets, up from 19% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Desktop Metal, Inc., an estimated $42.7M trimmed.

  • Alphabet Inc's largest Q2 2021 buy was UiPath: 29,025,785 shares worth $1.97B.
  • Alphabet Inc added most to Relay Therapeutics in Q2 2021, an estimated $8.52M increase.
  • Alphabet Inc's biggest Q2 2021 reduction was Desktop Metal, Inc., cutting an estimated $42.7M.
  • Alphabet Inc fully exited Upstart Holdings in Q2 2021, selling an estimated $107M.
  • Alphabet Inc's ten largest holdings make up 89% of its $4.91B portfolio in Q2 2021.
  • Alphabet Inc opened 8 new positions and closed 4 in Q2 2021.
  • Alphabet Inc's portfolio value rose 98% quarter-over-quarter to $4.91B.

Based on Alphabet Inc's 13F filing for Q2 2021, filed 15 Nov 2022.